EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Real-World Data on First Relapse in Multiple Myeloma: Treatment Patterns and Outcomes in Finland Using Automated Data Collection

Johanna Vikkula, Kari Remes, Outi Laatikainen, Merja Utriainen, Saara Tikka, Juha Lievonen

Acta Haematologica · 12.06.2026 · 1-12

DOI: 10.1159/000552684 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Acta Haematologica, online erschienen am 12.06.2026. Verfasst von Johanna Vikkula und 5 weiteren Autor:innen. Beteiligte Einrichtung: Medaffcon Oy, Espoo, Finland. Die Arbeit nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

This study aimed to characterize multiple myeloma (MM) patients at the first relapse and examine treatment outcomes.

Methods

This registry-based retrospective study examined relapsed MM patients in two Finnish Wellbeing Services Counties (Helsinki and Uusimaa, and Southwest Finland) from 2013 to 2022. Relapse was identified per current guidelines using serum paraprotein, plasma immunoglobulins, and free light chain data. Data were collected from hospital data lakes, Social Insurance Institution and Digital and Population Services Agency. Patients were stratified by age (≤70 vs. >70), index year, and time to first relapse (≤2 vs. >2 years post-diagnosis).

Results

Of 1,221 patients treated for MM between 2012 and 2022, 286 met the study inclusion criteria. Median overall survival from the relapse was higher in the younger patients (32.4 months vs. 20.0 months). In the first half of follow-up, lenalidomide was the most common pharmacotherapy in both age groups. After 2018, CD38-based treatments and pomalidomide increased significantly for younger patients, remaining limited in the elderly.

Conclusion

While new therapies have been adopted for younger MM patients, the treatment of older patients at first relapse has had little change. Given their poorer outcomes, there is a need to improve care for older MM patients.

Schlagwörter

Stichwörter der Autor:innen

EpidemiologyMultiple myelomaOncohematologyReal-world evidenceRelapse

Autor:innen und Institutionen

  • Medaffcon Oy, Espoo, Finland.
  • Turku University, Turku, Finland.
  • Medaffcon Oy, Espoo, Finland, outi.laatikainen@medaffcon.com.
  • GSK Oy, Helsinki, Finland.
  • Helsinki University Hospital, Comprehensive Cancer Center, Helsinki, Finland.

Zitieren

APA

Vikkula, J., Remes, K., Laatikainen, O., Utriainen, M., Tikka, S., & Lievonen, J. (2026). Real-World Data on First Relapse in Multiple Myeloma: Treatment Patterns and Outcomes in Finland Using Automated Data Collection. Acta Haematologica, 1-12. https://doi.org/10.1159/000552684

Vancouver

Vikkula J, Remes K, Laatikainen O, Utriainen M, Tikka S, Lievonen J. Real-World Data on First Relapse in Multiple Myeloma: Treatment Patterns and Outcomes in Finland Using Automated Data Collection. Acta Haematologica. 2026:1-12. doi:10.1159/000552684

BibTeX
@article{Vikkula2026,
  author = {Vikkula, Johanna and Remes, Kari and Laatikainen, Outi and Utriainen, Merja and Tikka, Saara and Lievonen, Juha},
  title = {Real-World Data on First Relapse in Multiple Myeloma: Treatment Patterns and Outcomes in Finland Using Automated Data Collection},
  journal = {Acta Haematologica},
  year = {2026},
  pages = {1--12},
  doi = {10.1159/000552684}
}
Kostenlos starten →